Dosage Visits European Cannabis Symposium in Copenhagen
Dosage went to European Cannabis symposium in Copenhagen 2019
By Dr Julie Moltke
A hub for the cannabis business and science leaders of Europe, hosted by American MJBiz.
Coming almost straight from the colourful Women’s health conference in London, the European Cannabis symposium had a completely different vibe. Bright tracksuits and protein bars were exchanged for fancy tailored suits and stacks of business cards. The event was hosted by MJBiz Daily, an American based marihuana business news agency established in 2011, and it was sponsored by several big cannabis related companies like Aurora, Medican and Isodiol.
The conference featured 42 international speakers, covering the three main topics: business and investment opportunities, policy, regulations and industry structure and last, science and technology. The focus was mainly on the immature European market, and a few speakers were looking with inspiration towards the cool older brother: the fast-developing North American market.
The medicinal cannabis scheme in Denmark
With Denmark as one of the countries in the forefront of the European medicinal cannabis development, Copenhagen was a natural choice of location, and the Grand Ballroom was full of smart businessmen and women ready to receive the key take away points about how to invest and handle the European market in the coming years.
The Danish minister of Health Ellen Trane Nørby made it crystal clear that the priority will always be the patients. She highlighted the story of a 28 year old electrician, who after having suffered electric shock through his body was struggling with constant migraine and fatigue to the degree that he could neither work nor attend to his family. After trying all possible existing treatments, he was enrolled into the Danish medical cannabis scheme, and slowly he regained his life. He went back to being the father and husband he had been before the accident.
She stressed the fact that science has always been innovative and that doctors should be open to experimenting in these early stages to find the benefits and the limitations of medicinal cannabis.
We are lacking the right clinical evidence
Rikke Jakobsen, CEO of Cannabis Denmark, a nongovernmental organisation that provides medical cannabis information to danish politicians, physicians, patients and cultivators pointed out that among the more than 800 cannabis studies taking place as you read this, the quality and the study design is often not good enough. She underlined the importance of investing much more time and money in clinical trials to determinate the safety, the efficacy and the long-term effects of cannabis on humans.
Malta is drawing attention as the new hot-spot for the medicinal cannabis industry
‘To change the demographics and spice things up a little let’s turn towards Malta, a small country who joined the cannabis hype in 2018 when they put forward an act that allowed for medicinal cannabis research and production to be carried out on the Island. The new regulation made Malta to the cannabis industry, what Luxembourg is to tax evaders. Malta was heavily represented at the fair, and it seemed that, like in Denmark, the government is currently trying to find a perfect balance between business, science and regulations, to benefit all parties.
A general trend seems to be the wish to continue the dialogue and education of medical practitioners about cannabis to benefit the most important group of all: the European patients.